Literature DB >> 9407346

Recent developments in autoimmune liver diseases.

M P Manns1.   

Abstract

Several diseases are regarded as autoimmune liver diseases. Apart from the cholestatic liver diseases, primary biliary cirrhosis, primary sclerosing cholangitis, these include autoimmune hepatitis, hepatitis as part of the autoimmune polyendocrine syndrome type 1 (APS-1) and particular overlap syndromes such as autoimmune cholangitis (also called antimitochondrial antibody negative primary biliary cirrhosis [PBC]), overlap syndrome chronic active hepatitis (CAH)/PBC and the overlap syndrome primary sclerosing hepatitis (PSC)/CAH. In addition, auto-antibodies may be observed during the course of chronic viral hepatitis, in particular chronic hepatitis C and D. Finally, a small number of drug-induced liver diseases is immune mediated. The following article will review our recent progress in the field of autoimmune hepatitis including APS-1 and autoimmunity in viral hepatitis and immune-mediated drug-induced liver disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9407346     DOI: 10.1111/j.1440-1746.1997.tb00509.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  3 in total

Review 1.  Autoantibodies and overlap syndromes in autoimmune rheumatic disease.

Authors:  E C Jury; D D'Cruz; W J Morrow
Journal:  J Clin Pathol       Date:  2001-05       Impact factor: 3.411

2.  Diagnosing clinical subsets of autoimmune liver diseases based on a multivariable model.

Authors:  Mikio Zeniya; Fumitoki Watanabe; Toshio Morizane; Minoru Shibata; Shiro Maeyama; Masayoshi Kage; Yasuni Nakanuma; Gotaro Toda
Journal:  J Gastroenterol       Date:  2005-12       Impact factor: 7.527

3.  Type 1 autoimmune hepatitis in Taiwan: diagnosis using the revised criteria of the International Autoimmune Hepatitis Group.

Authors:  Lok-Beng Koay; Ching-Yih Lin; Sun-Lung Tsai; Chuan Lee; Ching-Nan Lin; Ming-Juen Sheu; Hsing-Tao Kuo; Chi-Shu Sun
Journal:  Dig Dis Sci       Date:  2006-10-20       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.